The global cushing’s syndrome diagnostic & treatment market is expected to grow at a compound annual growth rate of 8.94% over the forecast period to reach a market size of US$555.415 million in 2027, from US$305.004 million in 2020.
Cushing’s disease is a condition characterised by the presence of excess steroid hormone “cortisol”’ or stress hormone in blood vessels and is caused by improper functioning of the pituitary glands, which are responsible for secreting adrenocorticotropic hormone (ACTH). ACTH stimulates the adrenal glands (located on top of the kidneys) to produce cortisol. Typical symptoms of Cushing’s syndrome are weight gain, the appearance of pink or purple stretch marks, thinning, and easily bruised skin. and occasionally type 2 diabetes. Treatment includes reducing the use of corticosteroids, surgery, and medications.
The market is expected to surge in the coming years, due to the rise in the number of Cushing syndrome cases, worldwide. In the United States, according to the American Association of Neurological Surgeons, an estimated number of 10-15 per million people are affected annually. Moreover, pituitary adenomas, which are a major cause of Cushing disease, usually account for over 70% of total cases in adults and around 60% of cases in adolescents and children. According to the data given by the European Union, the prevalence rate of endogenous Cushing syndrome is around 1/26,000 worldwide, and in the European Union, it has a yearly incidence of 1/1,4000,000 with an extraordinary peak incidence at 25-40 years of age. These trends and developments are expected to spur the market’s growth in the coming years.
Major companies have been making significant developments in the market. With the rise in the number of Cushing syndrome diseases, the demand for novel treatment and diagnostic solutions is expected to surge. This has led to an increase in investment from various firms worldwide.
In March 2020, the United States Food and Drug Administration announced that it had approved Isturis oral tablets specifically for adults with Cushing's disease, who have undergone the surgery, but still have the disease, or cannot undergo pituitary gland surgery. The FDA had approved this novel drug based on the drug's study among 137 adult patients. The overall test results and study were positive. The approval had been granted to a major player, Novartis.
In March 2021, PGI doctors announced that they had developed a technique to treat Cushing syndrome. The doctors had developed a technique to locate the tumour in the pituitary gland, which has been a major cause of Cushing syndrome. The technique has been named Ga-68 CRH PET-CT. This development is expected to have a positive impact on the market.
In May 2021, Sparrow Pharmaceuticals, one of the major players in the market, announced that it had been planning to launch a novel Phase 2 clinical trial to assess the overall effectiveness and safety of lead small molecule, and investigational HSD-1 inhibitor, also known as SPI-62, in people suffering from Cushing's syndrome. The company had stated that the novel trial had been expected to open later in 2021, and it would enrol people with Cushing syndrome who have at least one of the following conditions: hyperlipidemia, impaired glucose tolerance, and type 2 diabetes.
In May 2021, the FDA announced that it had accepted a review of a novel drug application for the respective steroidogenesis inhibitor for the respective treatment of endogenous Cushing's syndrome. Major companies have welcomed this decision. Strongbridgge Biopharma, one of the major players in the market, had stated that they had been pleased with the FDA's acceptance and approval for the filing of the Recorlav novel drug application. This development is expected to play a major role in the market’s growth in the coming years.
Surgery is expected to have a major share in the market.
There are several ways and methods to treat Cushing’s syndrome. Surgery is expected to have a major share of the market growth, as most patients have been opting for surgical procedures and methods globally. If the major cause of the problem is the tumour, then the doctor recommends a complete surgical removal process. Hospitals have been spending a significant sum of capital to develop novel surgical procedures, worldwide. For instance, in India, Apollo Hospitals Enterprise Ltd., offers surgical procedures and methods for their patients. The hospitals, to register more patients, have been investing a significant sum of capital into the adoption of novel and new machinery, and equipment. The growth of the e-Health and online sectors is also expected to have a positive impact on the market.
|Market size value in 2020||US$305.004 million|
|Market size value in 2027||US$555.415 million|
|Growth Rate||CAGR of 8.94% from 2020 to 2027|
|Forecast Unit (Value)||USD Million|
|Segments covered||Diagnostic Test, Treatment, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Novartis, Corcept Therapeutics Inc., StrongBridge Biopharma, Orphagen Pharmaceuticals Inc., HRA Pharma, Sparrow Pharmaceuticals, Cyclacel Pharmaceuticals|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Q1. What will be the Cushing's syndrome diagnostic & treatment market size by 2027?
A1. The global Cushing's syndrome diagnostic & treatment market is expected to reach a total market size of US$555.415 million in 2027.
Q2. What are the growth prospects for the Cushing's syndrome diagnostic & treatment market?
A2. The global Cushing's syndrome diagnostic & treatment market is expected to grow at a CAGR of 8.94% over the forecast period.
Q3. What is the size of the global Cushing's syndrome diagnostic & treatment market?
A3. Cushing's Syndrome Diagnostic And Treatment Market was valued at US$305.004 million in 2020.
Q4. What factors are anticipated to drive the Cushing's syndrome diagnostic & treatment market growth?
A4. The market is expected to surge in the coming years, due to the rise in the number of Cushing syndrome cases, worldwide.
Q5. How is the global Cushing's syndrome diagnostic & treatment market segmented?
A5. The Cushing's syndrome diagnostic & treatment market has been segmented by diagnostic test, treatment, and geography.
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Diagnostic Test
5.2. Urine & Blood Test
5.3. Saliva Test
5.4. Imaging Tests
5.5. Petrosal Sinus Sampling
6. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Treatment
6.3. Radiation Therapy
7. Global Cushing’s Syndrome Diagnostic & Treatment Market Analysis, By Geography
7.2. North America
7.2.1. United States
7.3. South America
7.5. Middle East and Africa
7.5.1. Saudi Arabia
7.6. Asia Pacific
7.6.4. South Korea
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.2. Corcept Therapeutics Inc.
9.3. StrongBridge Biopharma
9.4. Orphagen Pharmaceuticals Inc.
9.5. HRA Pharma
9.6. Sparrow Pharmaceuticals
9.7. Cyclacel Pharmaceuticals
Corcept Therapeutics Inc.
Orphagen Pharmaceuticals Inc.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.